Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson & Johnson (J&J) and US private equity firm Platinum Equity over the sale of the
Novo Nordisk is working with a digital health start-up to link better medication adherence to lower medicine costs for diabetes patients in the US through a text messaging pilot.
